SOURCE: Radient Pharmaceuticals Corporation

December 28, 2009 17:38 ET

Radient Pharmaceuticals Informed by AMEX of Possible Delisting

TUSTIN, CA--(Marketwire - December 28, 2009) - Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) today announced it has received notice from the NYSE Amex that the Company is not in compliance with the continued listing standard in Section 1003(a)(iv) of the Exchange's Company Guide. The Company has until January 22, 2010 to submit a plan to regain compliance by June 23, 2010. If the Company does not submit a plan or if the plan is not accepted by the Exchange, or if our plan is accepted but we fail to make progress consistent with our plan, or we are not in compliance by June 23, 2010, the Company would be subject to delisting procedures.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    (Tel : ) 206.310.5323